The Obesity Drug War Turns Ugly: Novo Nordisk Sues Eli Lilly and Wall Street Already Picked a Side
Novo Nordisk just sued Eli Lilly over weight-loss drug ads, but the moment the lawsuit hit, investors moved in exactly the wrong direction for Novo. Here is what the stock reaction reveals about who is actually winning this war.
The polite duopoly running the modern weight-loss drug boom just filed for divorce, and the market voted before the ink dried. Novo Nordisk (NYSE:NVO | NVO Price Prediction) sued Eli Lilly (NYSE:LLY) over what it calls misleading US advertising for Zepbound, and on the news, Novo’s ADRs slipped about half a percentage point while Lilly’s stock rose. A lawsuit is supposed to be a threat, but investors read it as an admission.
You already know which side Wall Street was on going in. Lilly’s market cap sits at roughly $1.1 trillion against Novo’s roughly $200 billion. Over the past year, LLY is up more than 50% while NVO is down roughly 27%. That gap is the context for everything else here.
What The Lawsuit Is Actually About
The complaint is narrower than the headlines suggest. Lilly ran ads comparing Zepbound to an earlier, lower-dose version of Wegovy using older trial data — specifically, the highest doses of Zepbound and Mounjaro against the lower 1.7mg and 2.4mg doses of Wegovy and Ozempic. Novo recently secured FDA approval for a higher-dose Wegovy (7.2mg) and argues those comparisons are now outdated and deceptive. Lilly’s position is that it based its ads on the Surmount-5 head-to-head trial, calling that study the gold standard for direct drug comparisons. Novo did the polite corporate thing first, sending Lilly a cease-and-desist months ago. When Lilly kept running the ads, Novo filed suit in US District Court in New Jersey, seeking a permanent injunction and corrective advertising campaign.
On the science, Novo has a legitimate point. The higher-dose Wegovy approval came out of the STEP UP trial, where patients lost 18.8% of their body weight on average over 72 weeks. That materially changes the comparison. But litigation is a slow tool for solving a fast marketing problem, and by the time discovery starts, doctors will have written another quarter of prescriptions.
Why The Stock Reaction Tells The Real Story
There is a genuine consumer perception that Zepbound is better than Wegovy, with patients walking into doctors’ offices asking for Lilly’s drug by name. That demand signal shows up clearly on the income statement. Lilly’s Q1 2026 delivered $19.8 billion in revenue, up 56% year over year, with Mounjaro at $8.66 billion (+125%) and Zepbound at $4.16 billion (+80%). Non-GAAP EPS came in at $8.55, beating the $6.79 consensus.
Q2 2026, reported August 5, was even bigger. Revenue climbed 48% to $23 billion, with Mounjaro reaching $9.9 billion (+91%) and Zepbound generating $4.9 billion in US revenue alone, a 44% year-over-year gain. Non-GAAP EPS of $8.38 cleared the $6.01 analyst consensus by a wide margin. On the back of those results, Lilly raised its 2026 revenue guidance to $85 billion to $87 billion, up from the previous $82 billion to $85 billion range.
Novo’s trajectory looked different heading into the lawsuit. First-quarter adjusted sales fell 4% at constant exchange rates, EPS of $6.63 missed the $6.96 consensus, and management guided full-year adjusted sales to between -4% and -12% at CER. The company also telegraphed list-price cuts of roughly 50% on Wegovy and 35% on Ozempic effective January 1, 2027. When you are cutting price by half, a court filing about ad copy is not the lever that saves you. Novo’s Q2 did show some recovery, with adjusted sales rising 7% at CER on strong GLP-1 volume, though reported operating profit fell 16% partly due to a DKK 6.3 billion non-cash impairment charge on pipeline assets including experimental drug monlunabant.
How Novo Lost Its Lead And Whether A Lawsuit Can Win It Back
Novo essentially invented the modern GLP-1 category, and then Lilly out-executed it. Lilly launched a direct-to-consumer website and cut cash-pay prices before Novo did, while moving aggressively to out-innovate on dosing and delivery. Novo’s response has been dramatic: a new CEO in Mike Doustdar, roughly 9,000 job cuts, and a broad culture overhaul.
The oral pill launch shows the franchise is still fighting. The Wegovy pill generated DKK 2,256 million in its first full quarter, captured 65% of new US prescriptions in the oral GLP-1 category at launch, and surpassed 5 million total prescriptions by the end of Q2. Weekly prescriptions exceeded 265,000 for the week ending July 17. That is not a company being lapped.
Lilly countered with Foundayo, its own oral GLP-1 pill approved by the FDA on April 1, 2026. Foundayo is a small-molecule drug, not a peptide, which means it can be taken any time of day without food or water restrictions, a meaningful convenience advantage over Wegovy pill. In the ATTAIN-1 trial, it produced 12.4% average body weight loss at 72 weeks. Since July 1, Medicare beneficiaries have been able to access both Foundayo and Zepbound for $50 per month, a structural tailwind that benefits Lilly’s larger injectable franchise in particular.
A pipeline setback has added to Novo’s pressures. Its next-generation injectable candidate CagriSema failed to match Lilly’s tirzepatide in a head-to-head diabetes trial (Reimagine 4), a result that undercut one of Novo’s key arguments for future competitive parity. The analyst consensus target on LLY now stands well above $1,000 per share versus roughly $47 for NVO. The Street’s verdict is not subtle.
The Verdict For Investors
A lawsuit does not fix a perception problem, and perception is what Novo needs to change. Lilly enters this fight with a bigger and faster-growing franchise, an approved oral pill free of food restrictions, and a stock that has dramatically outpaced Novo’s over any meaningful time horizon. Novo is still enormously profitable, its oral launch is real, and its Q2 recovery showed some momentum. But the burden of proof has flipped. Lilly has to keep executing. Novo has to convince patients and doctors that the newer, higher-dose Wegovy is worth switching to, and no court order will do that for them.
Editor’s note: This update corrects the weight-loss figure for high-dose Wegovy from “nearly 21%” to the STEP UP trial result of 18.8%, adds Lilly’s Q2 2026 results (revenue $23 billion, Mounjaro $9.9 billion, Zepbound $4.9 billion, and raised full-year guidance to $85-87 billion), incorporates Novo’s Q2 2026 recovery in adjusted sales (+7% at CER), notes the Wegovy pill surpassing 5 million total US prescriptions, updates Novo’s market cap to roughly $200 billion, adds the April 1, 2026 FDA approval of Foundayo, and flags the Medicare GLP-1 coverage launch on July 1 and the CagriSema setback in the Reimagine 4 trial.
Contact [email protected] for any questions or corrections.
Omor Ibne Ehsan is a writer at 24/7 Wall St. He is a self-taught investor with a focus on growth, cyclical, and dividend equities that have strong fundamentals, value, and long-term potential. He also has an interest in high-risk, high-reward investments such as penny stocks.
